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Introduction {#sec001}
============

Alcohol consumption is documented to exert multiple consequences on human health. Alongside the well-known harmful effects of alcohol abuse, the real impact of moderate assumption is more complex to elucidate. Several epidemiological studies described a J-shaped correlation between alcohol intake and cardiovascular disease, depicting a dose-related combination of beneficial and harmful effects \[[@pone.0233619.ref001]\]. Moderate drinkers show lower cardiovascular risk compared to both heavy drinkers and abstainers \[[@pone.0233619.ref002]--[@pone.0233619.ref004]\]. Indeed, a moderate alcohol consumption, defined as up to 1 drink (12 g of ethanol) daily for women and up to 2 for men, seems to have beneficial effects on general health. In this context, an alcohol-mediated protective action is largely proposed in the cardiovascular setting and numerous underlying mechanisms have been advocated, such as high-density lipoprotein (HDL) increase, low-density lipoprotein (LDL) decrease, reduction in platelet aggregation, beneficial effects on inflammation, anti-atherogenesis and anti-thrombotic actions \[[@pone.0233619.ref005]\]. Although the qualitative difference between the various alcoholic beverages does not seem to be decisive in reducing cardiovascular risk \[[@pone.0233619.ref006], [@pone.0233619.ref007]\], the *in vivo* effects of wine, beer or spirit assumption result significantly different. Positive effects of moderate alcohol consumption on mortality rate have been reported since the late seventies \[[@pone.0233619.ref008]\] and have later been reviewed and confirmed by several other papers \[[@pone.0233619.ref009]--[@pone.0233619.ref011]\]. Indeed, recent meta-analyses demonstrated an overall beneficial effect of both wine and beer consumption on cardiovascular risk and mortality, hypothesizing a fundamental action of the polyphenol content, which is absent in spirits \[[@pone.0233619.ref002], [@pone.0233619.ref012]--[@pone.0233619.ref014]\]. *In vitro* studies suggest a wine-related modulation in the expression of serum inflammatory and leucocyte adhesion molecules, such as the increase of interleukin (IL)-10 and decrease of IL-1α, IL-6, intracellular adhesion molecule (ICAM)-1, P-Selectin, monocyte chemoattractant protein (MCP)-1, and vascular cell-adhesion molecule (VCAM)-1 \[[@pone.0233619.ref012]\]. While the molecular mechanisms of wine action have been extensively studied, much less is known about beer effects, despite its widespread consumption all over the world \[[@pone.0233619.ref014]\].

Beer is a product of cereals fermentation and it is composed for 90% by water and for the remaining 10% by sugars, minerals, vitamins, amino acids, alcohol and polyphenols. Alongside the barley and hops-derived polyphenols, other beer ingredients added to impart additional flavours contribute to the polyphenolic content. In particular, the flavonoids depicted in beer are flavan-3-ols (catechin, epicatechin and gallocatechin), flavanols (kaempferol, myricetin and quercetin), and proanthocyanins. Among these, xanthohumol is a prenylated chalcone-type flavonoid representing a beer-specific polyphenol, since it is present exclusively in hop-derived products \[[@pone.0233619.ref015]\]. This molecule is suggested to confer beer-specific beneficial effects compared to other fermented alcoholic beverages, but this aspect needs further confirmation \[[@pone.0233619.ref013]\]. Yeasts are also used in the production of beer, as a means to make the drink alcoholic and carbonated. These organisms also produce several compounds having protective effect against degenerative diseases, such as melatonin, tryptophol and serotonin \[[@pone.0233619.ref016]\] which have also shown beneficial properties in cardiovascular prevention \[[@pone.0233619.ref017]--[@pone.0233619.ref020]\]. Regarding the alcoholic component, different kinds of beer are available with an alcohol content ranging from 3.5 to 10 percentage weight/volume (% w/v). A moderate beer consumption is defined by the World Health Organization (WHO) as up to a can of 330 mL of beer containing about 5% w/v alcohol daily for women and up to 2 for men \[[@pone.0233619.ref021]\]. The heterogeneous composition of beer represents one of the most interesting challenge in evaluating effects of alcoholic beverages on human health. Indeed, a hypothetical beneficial effect could be due to the action of either alcohol or polyphenols alone or a synergic effect of both.

Despite the large amount of data investigating the effect of alcoholic beverages on human health, a specific evaluation of the beer potential benefits is not available. Thus, the aim of this study was to provide a comprehensive evaluation of potential beer-mediated protective effects, focusing on the endothelial health.

Materials and methods {#sec002}
=====================

Protocol {#sec003}
--------

We performed this study according to the Cochrane Collaboration \[[@pone.0233619.ref022]\] and PRISMA statement.

Data sources and strategies {#sec004}
---------------------------

A comprehensive literature search was performed using the following search key words: beer, cardiovascular risk, cardiovascular disease, cardiovascular, endothelial function, endothelial dysfunction, and the Boolean operators AND and OR. All articles published in English language until November, 30^th^ 2019 in EMBASE, PubMed and Cochrane databases were evaluated. The meta-analysis was first registered in the International Prospective Register of Systematic Reviews (PROSPERO registration number: CRD42018118387). Articles were screened to exclude duplicates and trials not aimed at studying beer effects.

Eligibility criteria {#sec005}
--------------------

The following inclusion criteria were considered: (i) controlled study design; (ii) adult patients (older than 18 years); (iii) beer administration compared to alcohol-free beer, water, abstinence or placebo. Both sexes were considered eligible, as well as all beer preparations.

Data process and quality {#sec006}
------------------------

Two authors extracted data from all randomized controlled trials (RCTs) selected with regard to study design, year of publication, number of included/excluded subjects, inclusion and exclusion criteria and type of intervention. Data about cardiovascular health were extracted from included studies. Since several parameters have been proposed in the literature to evaluate the cardiovascular health, a work diagram was created to highlight those parameters reported in the vast majority of extracted studies. The primary endpoints considered in the analysis were lipid parameters.

The quality of RCTs was assessed using the Cochrane Risk of bias tool.

The procedures followed were in accordance with the ethical standards of the responsible institutional or regional committee on human experimentation or in accordance with the Helsinki Declaration of 1975 as revised in 2013. Considering the meta-analytic study design, ethics approval was not required.

Data synthesis and analysis {#sec007}
---------------------------

The available data were meta-analyzed using the Review Manager 5.2 software (Version 5.2.4 Copenhagen: The Nordic Cochrane Centre, The Cochrane Collaboration, 2012), using the random or fixed effect models, according to data heterogeneity. Heterogeneity between the results of different studies was examined by inspecting the scatter in the data points and the overlap in their confidence intervals and by performing chi-square tests and I^2^ statistics. When I^2^ was higher than 60%, random effect model was used since it provides a more conservative estimate of the overall effect, especially relevant when studies were of different design and duration. Weighted mean differences and 95% confidence intervals were estimated for each endpoint considered. The mean difference was calculated for each study included, using results reported as mean and standard deviation. When results were reported as median and standard error, these were used to calculate appropriate results.

Publication biases were evaluated inspecting the funnel plot, according to Cochrane collaboration and PRISMA statement. Moreover, the Egger's test was performed to exclude the presence of publication biases.

Sensitivity analyses were performed in order to reduce studies heterogeneity, considering the duration of beer administration in each study enrolled. Indeed, the acute beer administration was separated from the chronic administration. The acute or chronic administration was defined according to the amount of beer administered. In particular, the acute protocol provided a single beer assumption, followed by outcomes measurement. On the contrary, the chronic protocol consisted of many beer administrations in a prolonged time-frame interval and followed by the outcome detection. Sensitivity analyses were performed considering the gender and the health status of the subjects for the significant parameters.

In order to evaluate the alcohol contribution to the potential beneficial effect, meta-regression analyses were performed considering the amount of alcohol used in each trial. Meta-regression analyses were performed using RStudio Server Open Source Edit Version 0.99.902 2016 and R programming software.

Statistical significance was set at p \<0.05.

Results {#sec008}
=======

The literature search detected 2,526,967 studies. After duplicates removal and fitting the search on clinical trials in humans, the final number of articles was 131,495. Among these studies, 69 papers were selected after title and abstract evaluation. [Table 1](#pone.0233619.t001){ref-type="table"} reported included studies characteristics and [S1 Table](#pone.0233619.s012){ref-type="supplementary-material"} showed excluded studies and reasons for exclusion. Twenty-six RCTs fully fulfilled inclusion and exclusion criteria and were used for data extraction \[[@pone.0233619.ref011], [@pone.0233619.ref014], [@pone.0233619.ref023]--[@pone.0233619.ref046]\] ([Fig 1](#pone.0233619.g001){ref-type="fig"}). Among studies enrolled, five trials considered an acute beer administration.

![Flow diagram showing the literature search process.](pone.0233619.g001){#pone.0233619.g001}
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###### Included studies characteristics.

![](pone.0233619.t001){#pone.0233619.t001g}

  Author                                            Journal                            Intervention                        n     Age (years)     Gender                Inclusion criteria         Aim of the study                                                                    Alcohol content   Duration (weeks)   Endpoints evaluated
  ------------------------------------------------- ---------------------------------- ----------------------------------- ----- --------------- --------------------- -------------------------- ----------------------------------------------------------------------------------- ----------------- ------------------ -------------------------------------------------------------------------------------------------------------------------
  Padro T \[[@pone.0233619.ref014]\]                Nutrients, 2018                    Beer, alcoholic and not-alcoholic   36    48.3±5.4        Both (21 M, 15 F)     Overweight                 Weight, lipoproteins and vascular endothelial function                              M: 10 g daily     4                  cholesterol, hs-CRP, TNF, IL-6, blood pressure, glucose, ASAT, GGT, weight, BMI, waist circumference
  F: 5 g daily                                                                                                                                                                                                                                                                                                             
  Tomita J \[[@pone.0233619.ref040]\]               Biochem Biophys Res Commun. 2017   Isomerized hop extract              23    28.5±3          Male                  Healthy                    Endothelial functions in smokers and non-smokers                                    NA                acute              FMD
  Schrieks IC \[[@pone.0233619.ref039]\]            Alcohol 2016                       Beer, alcoholic and not-alcoholic   24    30.5±16.6       Male                  Healthy                    Mental stressor attenuates the stress response                                      26 g              acute              Stroop task, Trier Social Stress Test, ACTH, Cortisol, DHEA, Interleukins, TNF
  Morimoto-Kobayashi Y \[[@pone.0233619.ref033]\]   Nutr J. 2016                       Matured hop bitter acids            200   44.5±1.2        Both (100 M, 100 F)   Overweight                 Abdominal body fat reduction                                                        35 mg daily       12                 Body weight, visceral fat, BMI, waist and hip circumference, blood pressure, cholesterol, glucose
  Chiva-Blanch G \[[@pone.0233619.ref026]\]         Nutr Metab Cardiovasc Dis. 2015    Beer, alcoholic and not-alcoholic   33    61±6            Male                  High cardiovascular risk   Cardiovascular risk                                                                 30 g daily        4                  Apolipoprotein A1, adiponectin, cholesterol, Interleukins, MCP-1, VCAM-1, TNF, weight, BMI, waist and hip circumference
  Karatzi K \[[@pone.0233619.ref032]\]              Nutrition 2013                     Beer, alcoholic and not-alcoholic   17    28.5±5.2        Male                  Healthy                    Cardiovascular risk                                                                 6 g               acute              Blood pressure, FMD, Pulse wave velocity
  Joosten MM \[[@pone.0233619.ref031]\]             Metabolism. 2011                   Beer, alcoholic and not-alcoholic   24    23.9±4.3        Female                Healthy                    Adiponectin                                                                         26 g daily        3                  Adiponectin, glucose, insulin, cholesterol
  Imhof A \[[@pone.0233619.ref030]\]                Diabetes Care. 2009                Wine, Beer, Vodka                   72    Range 22--56    Both (36 M, 36 F)     Healthy                    Diabetes risk and cardiovascular mortality                                          M: 30 g daily     3                  Adiponectin
  F: 20 g daily                                                                                                                                                                                                                                                                                                            
  Imhof A \[[@pone.0233619.ref029]\]                Diab Vasc Dis Res. 2008            Wine, Beer, Vodka                   49    Range 22--56    Both (25 M, 24 F)     Healthy                    Monocyte migration                                                                  M: 30 g           acute              MCP-1,TNF, cholesterol
  F: 20 g                                                                                                                                                                                                                                                                                                                  
  Tousoulis D \[[@pone.0233619.ref041]\]            Clin Nutr. 2008                    Beer                                83    25.1±2          Male                  Healthy                    Endothelial function, inflammatory process and thrombosis/fibrinolysis system       30 g              acute              Glucose, Interleukin-6, cholesterol, TNF, PAI-1, tPA
  Beulens JW \[[@pone.0233619.ref025]\]             Nutr Metab Cardiovasc Dis. 2008    Beer, alcoholic and not-alcoholic   20    20±2            Male                  Healthy                    Lipoprotein-associated phospholipase A2 activity                                    40 g daily        3                  Phospholipase A2 activity, cholesterol, BMI, hs-CRP, blood pressure
  Romeo J \[[@pone.0233619.ref037]\]                Nutr Metab Cardiovasc Dis. 2008    Beer                                57    M: 35±6.1       Both (30 M, 27 F)     Healthy                    Blood lipid profile                                                                 M: 22 g daily     4                  Waist and hip circumferences, cholesterol, glucose
  F: 37.6±9.2                                                                                                                                                                                                                                                                                                              
  F: 11 g daily                                                                                                                                                                                                                                                                                                            
  Romeo J \[[@pone.0233619.ref038]\]                Ann Nutr Metab. 2007               Beer                                57    M: 35±6.1       Both (30 M, 27 F)     Healthy                    Immune function                                                                     M: 22 g daily     4                  Interleukins, IFN, TNF
  F: 37.6±9.2                                                                                                                                                                                                                                                                                                              
  F: 11 g daily                                                                                                                                                                                                                                                                                                            
  Addolorato G \[[@pone.0233619.ref023]\]           Appetite 2008                      Wine, Beer, Spirits                 40    28±6            Male                  Healthy                    Oxidative stress and nutritional parameters                                         40 g daily        4                  Malondyaldeide, adenosine-triphosphate, reduced-glutathione, fat mass, cholesterol
  Beulens JW \[[@pone.0233619.ref024]\]             Eur J Clin Nutr. 2008              Beer, alcoholic and not-alcoholic   20    20±2            Male                  Healthy                    Adipokines and insulin sensitivity                                                  40 g daily        3                  Acylation-stimulating protein, adiponectin, glucose, insulin, leptin
  Zilkens RR \[[@pone.0233619.ref044]\]             Hypertension. 2005                 Wine, beer                          24    53.3±7.7        Male                  Healthy                    Vascular function                                                                   41 g daily        4                  Blood pressure, FMD, glyceryl trinitated-mediated
  Zilkens RR \[[@pone.0233619.ref045]\]             J Hypertens. 2003                  Beer                                16    51±19.8         Male                  Healthy                    Conduit artery endothelial function in moderate-to-heavy drinkers (40--110 g/day)   9.8 g daily       4                  FMD, GGT, cholesterol, homocysteine blood pressure
  Sierksma A \[[@pone.0233619.ref011]\]             Eur J Clin Nutr. 2002              Beer                                20    M: 55±6         Both (10 M, 10 F)     Healthy                    The acute phase proteins C-reactive protein and fibrinogen                          M: 40 g daily     6                  plasma CRP, fibrinogen, HDL, triglycerides, ALAT, ASAT, GGT
  F: 57±4                                                                                                                                                                                                                                                                                                                  
  F: 30 g daily                                                                                                                                                                                                                                                                                                            
  van der Gaag MS \[[@pone.0233619.ref043]\]        J Lipid Res. 2001                  Beer, Wine, Spirits                 11    Range 45--60    Male                  Healthy                    The first two steps of the reverse cholesterol pathway                              40 g daily        3                  Apolipoprotein A1, cholesterol, paraoxonase
  van der Gaag MS \[[@pone.0233619.ref042]\]        Atherosclerosis. 1999              Beer, Wine, Spirits                 11    51.7±5.4        Male                  Healthy                    Paraoxonase activity in serum                                                       40 g daily        3                  paraoxonase activity, apolipoprotein A1, cholesterol
  Dimmitt SB \[[@pone.0233619.ref027]\]             Blood Coagul Fibrinolysis. 1998    Beer                                55    Range: 20--63   Male                  Healthy                    Incidence of ischaemic events                                                       7.8 g daily       4                  fibrinogen, PAI-1, tPA
  Gorinstein S \[[@pone.0233619.ref028]\]           J Intern Med. 1997                 Beer                                48    Range: 51--72   Male                  cardiovascular risk        Lipid metabolism and antioxidant activity                                           25 g daily        4                  cholesterol, tocopherol
  Puddey IB \[[@pone.0233619.ref036]\]              Hypertension. 1992                 Beer, alcoholic and not-alcoholic   86    Range: 25--70   Male                  Overweight                 Blood pressure and blood lipids                                                     3.2 g daily       18                 weight, blood pressure
  Puddey IB \[[@pone.0233619.ref034]\]              Lancet. 1987                       Low-alcoholic beer                  44    52.9±2.4        Male                  Hypertension               Blood pressure in hypertensive men                                                  6.4 g daily       12                 blood pressure
  Masarei JR \[[@pone.0233619.ref046]\]             Atherosclerosis. 1986              Beer                                48    Range: 25--55   Male                  Healthy                    Blood lipid profile                                                                 6.4 g daily       6                  cholesterol, apolipoprotein-A1
  Puddey IB \[[@pone.0233619.ref035]\]              Hypertension. 1985                 Beer                                46    Range: 25--55   Male                  Healthy                    Blood pressure                                                                      6.4 g daily       6                  blood pressure

\[ACTH = adrenocorticotropic hormone; ALAT = alanine aminotransferase; ASAT = aspartate aminotransferase; BMI = body mass index; DHEAS = dehydroepiandrosterone sulfate; F = female; FMD = flow mediated dilation; GGT = gamma-glutamyltransferase; HDL = high density lipoprotein; hs-CRP = high sensitivity C-reactive protein; IFN = interferon; IL-6 = interleukin 6; M = male; MMP3 = matrix metalloproteinase-3; MMP9 = matrix metalloproteinase-9; MCP-1 = monocyte chemoattractant protein-1; NA: not available; PAI-1 = plasminogen activator inhibitor-1; TMP1 = tropomyosin 1; tPA = tissue plasminogen activator; TNF = tumor necrosis factor; VCAM-1 = vascular cell adhesion protein 1\].

The analysis was limited to those parameters entering in the cardiovascular risk charts and those related to endothelial dysfunction. In general, the most reported parameters were: cholesterol, blood pressure, tumor necrosis factor (TNF), IL-6, flow mediated dilation (FMD), fibrinogen, body mass index (BMI), glucose, insulin, adiponectin and high sensitivity C-reactive protein (hs-CRP). However, not all parameters were available in all studies. Thus, we performed a work diagram ([S1 Fig](#pone.0233619.s001){ref-type="supplementary-material"}) in which the font dimension is directly related to the number of studies reporting each parameter. Considering those parameters reported in the vast majority of studies ([S1 Fig](#pone.0233619.s001){ref-type="supplementary-material"}), the analysis was limited to lipid profile, blood pressure, FMD, fibrinogen, adiponectin, hs-CRP, TNF and IL-6.

Total cholesterol was reported in 14 studies, comparing 548 beer drinkers and 532 controls. Total cholesterol was significantly higher in study compared to control group (mean difference 3.52 mg/dL, 1.71 to 5.32 mg/dL, p\<0.001, I^2^ = 65%) ([Fig 2](#pone.0233619.g002){ref-type="fig"}). Similar results were found when beer was compared to either alcohol-free beer (mean difference 3.00 mg/dL, 0.51 to 5.49 mg/dL, p = 0.020, I^2^ = 69%), or placebo/water (mean difference 3.92 mg/dL, 0.51 to 7.33 mg/dL, p = 0.020, I^2^ = 60%) ([Fig 2](#pone.0233619.g002){ref-type="fig"}). Sensitivity analysis was applied to reduce the source of heterogeneity. In studies evaluating only chronic administration of beer, the difference between study and control group was evident comparing beer to alcohol-free beer and not to placebo/water (mean difference 1.92 mg/dL, -4.35 to 8.19 mg/dL, p = 0.550, I^2^ = 65%). Moreover, no differences were observed dividing studies neither by patients' gender (p = 0.479) nor by health status (p = 0.301). Meta-regression analyses showed no relationship between total cholesterol and alcohol content (p = 0.652). Finally, no publication biases were found (p = 0.147).

![Forest plot reporting total cholesterol serum levels comparing study and control groups.](pone.0233619.g002){#pone.0233619.g002}

HDL cholesterol was reported in 18 studies, comparing 626 beer drinkers and 635 controls. HDL cholesterol significantly improved in study compared to control group (mean difference 3.63 mg/dL, 2.00 to 5.26 mg/dL, p\<0.001, I^2^ = 96%) ([Fig 3](#pone.0233619.g003){ref-type="fig"}). Similar results were found when beer was compared to either alcohol-free beer (mean difference 4.51 mg/dL, 2.23 to 6.79 mg/dL, p\<0.001, I^2^ = 96%), or placebo/water (mean difference 2.59 mg/dL, 0.74 to 4.45 mg/dL, p\<0.001, I^2^ = 93%) ([Fig 3](#pone.0233619.g003){ref-type="fig"}). In particular, significant higher apolipoprotein A1 levels were detected in study group, compared to control group (mean difference 0.16 mg/dL, 0.11 to 0.21 mg/dL, p\<0.001, I^2^ = 97%) ([Fig 4](#pone.0233619.g004){ref-type="fig"}). Sensitivity analysis confirmed these differences also considering exclusively studies assessing chronic administration of beer (mean difference 3.69 mg/dL, 1.74 to 5.63 mg/dL, p\<0.001, I^2^ = 92%). Similar results were obtained dividing studies according to gender (p = 0.709), whereas, the significant change in HDL cholesterol was lost in non-healthy subjects (p\<0.001). No relationship was found between HDL cholesterol and alcohol content (p = 0.798). Finally, no publication biases were found (p = 0.485).

![Forest plot reporting high density lipoprotein (HDL) cholesterol serum levels comparing study and control groups.](pone.0233619.g003){#pone.0233619.g003}

![Forest plot reporting apolipoprotein A1 serum levels comparing study and control groups.](pone.0233619.g004){#pone.0233619.g004}

LDL cholesterol was reported in 12 studies, comparing 459 beer drinkers and 635 controls ([S2 Fig](#pone.0233619.s002){ref-type="supplementary-material"}). LDL cholesterol was not significantly different between study and control groups (mean difference -2.85 mg/dL, -5.96 to 0.26 mg/dL, p = 0.070, I^2^ = 95%) ([S2 Fig](#pone.0233619.s002){ref-type="supplementary-material"}). This lack of difference was maintained also dividing studies considering alcohol-free beer (mean difference -3.13 mg/dL, -6.73 to 0.47 mg/dL, p = 0.090, I^2^ = 94%), or placebo/water (mean difference -2.36 mg/dL, -7.16 to 2.44 mg/dL, p = 0.330, I^2^ = 80%) ([S2 Fig](#pone.0233619.s002){ref-type="supplementary-material"}).

Triglycerides were reported in 14 studies, comparing 552 beer drinkers and 536 controls ([S3 Fig](#pone.0233619.s003){ref-type="supplementary-material"}). Triglycerides serum levels were not significantly different between study and control groups (mean difference 0.40 mg/dL, -5.00 to 5.80 mg/dL, p = 0.089, I^2^ = 91%) ([S3 Fig](#pone.0233619.s003){ref-type="supplementary-material"}). This lack of difference was maintained also dividing studies considering alcohol-free beer (mean difference 2.16 mg/dL, -7.89 to 12.22 mg/dL, p = 0.670, I^2^ = 96%), or placebo/water (mean difference -0.11 mg/dL, -1.94 to 1.71 mg/dL, p = 0.330, I^2^ = 0%) ([S3 Fig](#pone.0233619.s003){ref-type="supplementary-material"}). Sensitivity analysis showed confirmed the lack of significant difference (mean difference 0.54 mg/dL, -1.80 to 2.87 mg/dL, p = 0.720, I^2^ = 92%).

Blood pressure was evaluated in 8 studies, comparing 363 to 347 subjects. Systolic blood pressure did not differ between study and control groups (mean difference 0.74 mmHg, -0.76 to 2.24 mmHg, p = 0.580, I^2^ = 97%) ([S4 Fig](#pone.0233619.s004){ref-type="supplementary-material"}). Similar lack of difference was maintained considering alcohol-free beer (mean difference 1.01 mmHg, -1.41 to 3.43 mmHg, p = 0.410, I^2^ = 96%) and water/placebo (mean difference 0.07 mmHg, -2.30 to 2.43 mmHg, p = 0.960, I^2^ = 98%) ([S4 Fig](#pone.0233619.s004){ref-type="supplementary-material"}). Similarly, diastolic blood pressure did not differ between study and control groups (mean difference 0.15 mmHg, -1.07 to 1.38 mmHg, p = 0.800, I^2^ = 98%), also considering alcohol-free beer (mean difference 1.46 mmHg, -0.02 to 2.94 mmHg, p = 0.050, I^2^ = 94%) and water/placebo (mean difference -1.73 mmHg, -3.47 to 0.00 mmHg, p = 0.050, I^2^ = 98%) ([S5 Fig](#pone.0233619.s005){ref-type="supplementary-material"}). Sensitivity analysis showed confirmed the lack of significant difference (mean difference 0.83 mmHg, -0.71 to 2.37 mmHg, p = 0.290, I^2^ = 97%).

FMD was reported in 4 studies, resulting significantly higher in the study group compared to controls (mean difference 0.65%, 0.07 to 1.23%, p = 0.030, I^2^ = 85%) ([Fig 5](#pone.0233619.g005){ref-type="fig"}). Considering other biochemical markers of inflammation, no differences were detected for TNF (5 studies, mean difference 0.00 ng/mL, -0.14 to 0.13 ng/mL, p = 0.960, I^2^ = 85%) ([S6 Fig](#pone.0233619.s006){ref-type="supplementary-material"}), IL-6 (5 studies, mean difference -1.89 ng/mL, -3.97 to 0.19 ng/mL, p = 0.080, I2 = 91%) ([S7 Fig](#pone.0233619.s007){ref-type="supplementary-material"}), adiponectin (4 studies, mean difference 0.22 microg/mL, -0.21 to 0.64 microg/mL, p = 0.310, I^2^ = 93%) ([S8 Fig](#pone.0233619.s008){ref-type="supplementary-material"}), and hs-CRP (4 studies, mean difference -0.07 microg/mL, -0.34 to 0.19 microg/mL, p = 0.600, I^2^ = 69%) ([S9 Fig](#pone.0233619.s009){ref-type="supplementary-material"}). Sensitivity analysis was not performed, since the number of studies included is limited.

![Forest plot reporting flow mediated dilation (FMD) comparing study and control groups.](pone.0233619.g005){#pone.0233619.g005}

Publication bias was not evident in this setting ([Fig 6](#pone.0233619.g006){ref-type="fig"}). Risk of bias of was reported in [S10 Fig](#pone.0233619.s010){ref-type="supplementary-material"}, showing an overall good quality of RCTs included in the final analysis, considering selection, attrition and reporting biases. [S11 Fig](#pone.0233619.s011){ref-type="supplementary-material"} showed the risk of bias judged for each study included in the analysis. Slightly relevant was the risk of performance and detection biases, which reflected the difficulty to perform a real double-blind clinical trial in the setting of dietary influence on the cardiovascular health.

![Tunel plot for high density lipoprotein (HDL) cholesterol levels.](pone.0233619.g006){#pone.0233619.g006}

Discussion {#sec009}
==========

In Europe, the most prevalent alcoholic beverages are beer, wine and spirits in different proportions and beer represents, in several European countries, the most prevalent source of alcohol consumption (\>50%). In this meta-analysis we evaluated, for the first time, the specific effects of beer on human health, distinctly from other alcoholic beverages, such as wine and spirit. Beer consumption is associated with improvement of the vascular elasticity, detected by the increase of FMD and of the lipid profile with a significant increase of HDL cholesterol levels possibly sustained by a raise of apolipoprotein A1 serum levels.

The accumulation of cholesterol within macrophage in arterial wall and their transformation in foam cells represents the key step in the atherosclerosis progression. In this process, HDL has a protective role, promoting the reverse cholesterol transport from peripheral tissues, allowing the excretion of cholesterol out of the body \[[@pone.0233619.ref047]\]. Thus, considering its physiological role in lipid asset homeostasis, low HDL cholesterol levels represent an independent risk factor for cardiovascular diseases. Here, a relevant effect of beer consumption on cholesterol levels has been demonstrated by an increase of total cholesterol. This increase is supported by a significant raise of HDL level, regardless of a meaningless action on LDL and triglycerides. This is in line with several reports reporting how moderate alcohol consumption may be associated with an increase in either the concentrations or in the anti-oxidant properties of HDL cholesterol \[[@pone.0233619.ref014], [@pone.0233619.ref048]\]. Moreover, the increase of apolipoprotein A1 may represent the mechanism at the base of HDL increase. Padro et al. recently demonstrated that regular consumption of moderate amount (2 cans daily for men and 1 for women) of traditional beer for 4 weeks promoted atheroprotective properties of HDL, preventing LDL oxidation and inducing cholesterol efflux from macrophage \[[@pone.0233619.ref014]\]. Interestingly, the beneficial effect of beer on HDL cholesterol seems to be evident only in healthy subjects. This specific context should be further analysed by proper-designed trials.

A meta-analytic approach does not allow to discriminate whether lipid modulation is due to alcohol or to polyphenol compounds contained in beer products. Moreover, the alcoholic beverages composition could be extremely heterogeneous, involving a large number of compounds that could play a role in the detected final effect, maybe due to single or synergic mechanisms. As a confirm, meta-regression analyses do not highlight a direct effect of alcohol content on lipid asset, suggesting the action of other molecules. The polyphenols capability to affect the lipid metabolism raising HDL serum levels was suggested by a recent meta-analysis, in which all the possible polyphenol food sources were considered \[[@pone.0233619.ref049]\]. However, in the present work we considered only beer products, compared to placebo, water, abstinence or alcohol-free beers. Dividing the analysis according to the control group intervention and in particular comparing beer with alcohol-free beer, we aimed to discriminate the alcohol-mediated effects from those due to non-alcoholic components, such as polyphenols. Since the increase in HDL levels remains evident comparing beer assumption to both alcohol-free beer and water, the causal mechanism seems not to be an alcohol-specific competence. However, in quantitative terms, a more consistent HDL increase is observed comparing beer to alcohol-free beer than to water (4.51 *versus* 2.59 mg/dL), suggesting a leading role of alcohol, although not confirmed in meta-regression analyses considering the entire group of studies. Accordingly, previous *in vitro* studies on polyphenols derived from red wine, cocoa and green tea do not show an HDL functionality enhancement \[[@pone.0233619.ref050]\]. Thus, this beer-related improvement in lipid asset seems to be due mainly to the ethanol itself \[[@pone.0233619.ref015]\]. This effect could be related to the alcohol dehydrogenase (ADH) activity that, on the other hand, is largely demonstrated to be related to several alcohol-related diseases, such as liver \[[@pone.0233619.ref051]\] and esophageal squamous cell \[[@pone.0233619.ref052]\] cancers.

The beer-specific polyphenol xanthohumol exhibits anti-inflammatory properties in *in vitro* studies, inhibiting lipopolysaccharide (LPS)-induced cytokine, MCP-1 and IL-6 production \[[@pone.0233619.ref053]\]. In addition, the beer polyphenol content is suggested to mediate other cardioprotective actions, such as the increase of endothelial progenitor cells (EPC) and EPC-mobilizing factors, molecules able to repair endothelial damages \[[@pone.0233619.ref054]\]. However, in our study, we do not highlight a beer-related improvement of TNF, IL-6, adiponectin and hs-CRP. This lack of polyphenol-mediated improvement in endothelial dysfunction parameters could be simply attributable to the low number of RCTs evaluated or to the presence of other substances able to counteract the polyphenol action \[[@pone.0233619.ref054]\]. However, an improvement of FMD is detected despite the low number of studies, suggesting a strong effect of beer on endothelial cells and, thus, on vasodilation. FMD is a marker of vascular elasticity generally evaluated at brachial artery at baseline and after 5 minutes of arterial occlusion, showing a normal response to the reactive hyperemia of about 7--15% \[[@pone.0233619.ref055]\]. Even if the mean increase after beer consumption is only one tenth (0.65%) of the FMD normal value, the significance achieved despite the few included studies suggests a consistent beer-mediated capability to induce vasodilatation. However, this beneficial effect on endothelial function comes mainly from studies in which an acute beer administration is provided, confirming those studies in the literature in which a vascular endothelial function improvement is described after acute beer intake \[[@pone.0233619.ref041]\]. Indeed, the acute intake could lead to the heart rate increase, the peripheral arteries dilation and the blood pressure reduction.

Beer consumption does not affect blood pressure, neither systolic nor diastolic. This effect is in line with the different properties exhibited by the heterogeneous components of beer. Indeed, the beer-mediated action on blood pressure is due to the vasodilator action of polyphenol \[[@pone.0233619.ref056]\]. Accordingly, a blood pressure reduction is detected when polyphenols are administered through different oral sources \[[@pone.0233619.ref049]\], as well as when non-alcoholic polyphenol beer compounds are used \[[@pone.0233619.ref026]\]. On the other hand, the role of alcohol on blood pressure is still debated. Although the role of excessive alcohol intake on hypertension as well as the blood pressure improvement after alcohol reduction are well established \[[@pone.0233619.ref057]\], the action of moderate consumption is challenging. However, a possible alcohol-mediated capability to counteract the blood pressure-reducing action of beer polyphenols has already been suggested \[[@pone.0233619.ref054]\]. Moreover, age, gender and comorbidities of subjects enrolled represent independent factors able to interfere with the blood pressure status evaluation.

An inverse dose-effect correlation between vascular events and alcohol consumption was detected for wine \[[@pone.0233619.ref013], [@pone.0233619.ref058]\] and, more recently, for beer \[[@pone.0233619.ref013]\]. While a protective range of daily wine consumption (from 10--21 g to 41--72 g) has been proposed, the paucity of available studies do not allow to obtain the same result for beer or spirit \[[@pone.0233619.ref013]\]. In the studies considered in our meta-analysis, beer is administered in randomized clinical settings in moderate dosages, i.e. less than 330 mL daily. Although the identification of a range of beer safety is beyond the objectives of the present meta-analysis, our results suggest that a moderate beer consumption could exert beneficial effects either in prevention of dyslipidaemia or in vasodilation improvement.

The most reliable outcomes at evaluating the cardiovascular health remains the long-term incidence of major cardiovascular events and the consequent mortality. However, epidemiological studies on alcoholic beverages are limited to the impossibility to precisely assess the type and the amount of alcohol consumed. On the contrary, RCTs allow studying specific types and amounts of alcoholic beverages, although limiting the evaluation on indirect markers of cardiovascular diseases. Despite the clear advantages coming from a controlled clinical setting, RCTs are not free of biases. Indeed, almost all studies included in the analysis did not strictly consider the diet and the activity pattern, except with specific questionnaires \[[@pone.0233619.ref026]\]. Moreover, the different intervention used in control groups represents another important limit. Indeed, 14 studies (53.8%) compared beer to alcohol-free beers, allowing at detecting mainly the alcohol role, in spite of polyphenolic beer contents. Moreover, the dealcoholisation process provokes a significant loss of non-alcoholic compounds, including polyphenols. Thus, the polyphenol content of beer and alcohol-free beer is not necessarily the same. Finally, since the brand of beers used in RCTs is not always reported, a sub-analysis considering beer styles was not possible.

In conclusion, this is the first comprehensive meta-analysis evaluating beer properties in the cardiovascular setting, suggesting that a moderate beer consumption could beneficially affect HDL serum levels and blood vessels elasticity. However, whether any of our findings has any clinical relevance is a question largely left unanswered, as the small effect sizes do not allow us to reach definite conclusions in that direction. Although the long-term effects of beer consumption are not still understood, a beneficial effect of beer on endothelial function should be supposed.
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2、 Now that the conclusion of this manuscript is "moderate beer drinkers seem not to be discouraged." (in line 44-45), Table 1 should include the accurate beer consumption in each study in order to identity whether it is moderate beer consumption or not.

3、 In line 90-92, you mentioned "the aim of this study was to provide a comprehensive evaluation of potential beer-mediated protective effects, focusing on the cardiovascular health". According to previous studies, cardiovascular health may include weight change, lipid profile, vascular health, blood pressure, inflammation, glycemic control, microbial profile, coagulation and so on. However, why the keywords in your manuscript only included endothelial function? (in line 99-100) And why the primary endpoints considered in the analysis were only lipid parameters? (in line 116) Is this consistent with the study protocol?

4、 In line 135-137, how to define acute beer administration or chronic administration by the duration of beer administration in each study enrolled? And the results of sensitivity analyses should be presented in the main test or supplemental material. As the heterogeneity in your results is pretty high, more sensitivity analyses, such as stratified by age, sex, BMI and so on, should be implemented in order to explore the source of high heterogeneity.

5、 In line 148-152, you mentioned "The most reported parameters were: cholesterol, blood pressure, tumor necrosis factor (TNF), IL-6, flow mediated dilation (FMD), fibrinogen, body mass index (BMI), glucose, insulin, adiponectin and high sensitivity C-reactive protein (hs-CRP). Thus, the analysis was limited to those parameters entering in the cardiovascular risk charts (lipid profile and blood pressure) and those related to endothelial dysfunction (i.e. FMD, fibrinogen, adiponectin, hs-CRP, TNF and IL-6)". Since BMI, glucose and insulin were also the most reported parameters and were included in the cardiovascular risk charts, why your results did not include these results?

6、 In line 150-152, you said "the analysis was limited to...those related to endothelial dysfunction (i.e. FMD, fibrinogen, adiponectin, hs-CRP, TNF and IL-6)..". According to previous studies, adiponectin, hs-CRP, TNF and IL-6 should be categoried as inflammation, not as endothelial dysfunction. Fibrinogen should be categoried as coagulation, not as endothelial dysfunction. Please refer to "Haseeb S, Alexander B, Baranchuk A. Wine and Cardiovascular Health: A Comprehensive Review. Circulation. 2017;136(15):1434--1448."

7、 The retrieval strategies should be more standard and accurate, and should be better list in a table. Please refer to：Lin X, Zhang X, Guo J, et al. Effects of Exercise Training on Cardiorespiratory Fitness and Biomarkers of Cardiometabolic Health: A Systematic Review and Meta-Analysis of Randomized Controlled Trials. J Am Heart Assoc. 2015;4(7):e002014.

8、 Publication bias should be evaluated not only inspecting the Funnel plot, but also implementing the Begg's adjusted rank correlation test and the Egger's regression test.

9、 Mean difference in results and figures should be described as "Weighted mean difference (WMD)"

10、 In Figure 1, the reason for excluded records should be specified. And the "Study included in qualitative synthesis" box is redundant.

Reviewer \#2: The paper by Spaggiari et al. evaluated the potential effect of beer consumption on cardiovascular health, exemplified as lipid metabolism, endothelial function and blood pressure, using a meta-analytic approach. Totally twenty-six randomized controlled trials were included in the current analyses, beer consumption was associated with higher HDL cholesterol, apoA1 and FMD, whereas not related to blood pressure.

Brief review of the paper:

1\) In Abstract, lines 27-28, "...The literature search, comprising all English articles published until November, 30th 2018 in EMBASE..." was inconsistent with the time mentioned in methods (page 5, line 101). Please check.

2\) In the last sentence of Abstract, the authors conclude "moderate beer drinkers seem not to be discouraged". However, Table 1 reporting characteristic of included trials did not include the level of beer consumption. It was hard to conclude whether moderate or high beer drinkers was beneficial from the current analyses. Estimate of the regression coefficient could be used to illustrate the dose-dependent association between beer consumption and cardiovascular markers.

3\) Following Question 2, according to eligibility criteria mentioned in Methods (page 5, lines 105-109), only randomized studies were included, but Table 1 emphasized the "randomized trials" in study design which may cause confusion.

4\) Of note, wine and spirit-controlled studies were also included, were these active controlled regarded as water? (Figure 4)

5\) Please check the data collected in the current analyses carefully. For example, Table 1, the study by Puddey IB (Hypertension 1992) was done in 86 overweight men (not healthy men) for an 18-week intervention of low or normal alcohol intake (not beer, alcoholic and not-alcoholic).\[1\]

6\) The acute effect of beer should be separated from the long-term effect, especially on blood pressure and FMD. Acute beer consumption would increase heart rate, dilate peripheral arteries and therefore reduce blood pressure, whether the continuing decline after long-term of alcohol consumption was of interest.

\[1\] Puddey IB, Parker M, Beilin LJ, et al. Effects of alcohol and caloric restrictions on blood pressure and serum lipids in overweight men. Hypertension. 1992;20:533-41.
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Editorial assistant comments

1\. Please report the results of the risk assessment individually for each study included. Moreover, please update the literature search.

ANSWER: The risk assessment has been performed evaluating the publication biases, using the Eggert's regression as the reviewers suggested. The other risk of biases providing by Cochrane collaboration could not be performed in this kind of meta-analysis. We better explain this within the text. Moreover, we updated the literature search as reported in the methods section.

2\. In your Data Availability statement, you have not specified where the minimal data set underlying the results described in your manuscript can be found. PLOS defines a study\'s minimal data set as the underlying data used to reach the conclusions drawn in the manuscript and any additional data required to replicate the reported study findings in their entirety. All PLOS journals require that the minimal data set be made fully available. For more information about our data policy, please see <http://journals.plos.org/plosone/s/data-availability>.

ANSWER: Within the 'data availability' section in the submission process, we stated that "Since this is a meta-analysis, all relevant data are within the manuscript (figures and tables)".

Associate Editor

Comment 1

In addition to the comments raised by the two Reviewers, please also consider the following suggestions in your revision: 1. Please supply more information of the trials in Table 1, such as mean age, number of males and females if both sexes were included, the beer administration protocol, such as beer type in terms of percentage weight/volume, and duration of consumption.

ANSWER: We updated the table 1, including more data for each study included.

Comment 2

Would the effect of beer on cardiovascular health differ according to the consumption quantity in terms of gram of ethanol?

ANSWER: Thank you for your suggestion. We included a meta-regression analysis within the text (in both materials and methods and Results sections) to evaluate the role of alcohol content on the outcome change. In particular, we focused these further analyses on the main outcomes obtained (i.e. total and HDL cholesterol).

Comment 3

Figure 2 seemed redundant. Please consider reduce the number of figures by moving some figures from the main manuscript to the supplemental material.

ANSWER: We moved the figure 2 within supplementary materials. We changed all figures order within the text.

Reviewer \#1:

Comment 1

In line 84-86, you mentioned "A moderate beer consumption is generally defined as up to a can of 330 mL of beer containing about 4% w/v alcohol daily for women and up to 2 for men." Is there any related reference to support this definition? According to Ref. "Voskoboinik A, Prabhu S, Ling LH, et al. Alcohol and atrial fibrillation: a sobering review. J Am Coll Cardiol. 2016;68:2567--2576." , alcohol consumption has been defined as: light (\<7 standard drinks/week); moderate (7 to 21 standard drinks/week); and heavy (\>21 standard drinks/week), where 1 standard drink is approximately 12 g of alcohol. Furthermore, according to "The World Health Organization's Estimates of a Standard Drink for Conventional Alcoholic Beverages"（Babor TF, Higgins-Biddle JC. Brief Intervention for Hazardous and Harmful Drinking: A Manual for Use in Primary Care. Geneva, Switzerland: World Health Organization; 2001. <http://apps.who.int/iris/bitstream/10665/67210/1/WHO_MSD_MSB_01.6b.pdf>)，a standard drink for beer is a can of 330 mL containing about 5% w/v alcohol. Therefore, I think the definition of moderate beer consumption in your manuscript may be not appropriate.

ANSWER: Thank you for your observation. We referred to the WHO definition and we corrected the sentence as follows: "A moderate beer consumption is defined by the World Health Organization (WHO) as up to a can of 330 mL of beer containing about 5% w/v alcohol daily for women and up to 2 for men (21).", including the reference to Babor et al.

Comment 2

Now that the conclusion of this manuscript is "moderate beer drinkers seem not to be discouraged." (in line 44-45), Table 1 should include the accurate beer consumption in each study in order to identity whether it is moderate beer consumption or not.

ANSWER: We updated the table 1, including detailed information about beer consumption.

Comment 3

In line 90-92, you mentioned "the aim of this study was to provide a comprehensive evaluation of potential beer-mediated protective effects, focusing on the cardiovascular health". According to previous studies, cardiovascular health may include weight change, lipid profile, vascular health, blood pressure, inflammation, glycemic control, microbial profile, coagulation and so on. However, why the keywords in your manuscript only included endothelial function? (in line 99-100) And why the primary endpoints considered in the analysis were only lipid parameters? (in line 116) Is this consistent with the study protocol?

ANSWER: We changed the aim of the study, specifying the more focused endpoint: i.e. endothelial function instead of the most general cardiovascular function. To obtain the largest number of manuscripts on this topic, we enlarged the selection of study during the literature search, using potentially wide key words, such as "cardiovascular health", endothelial dysfunction" and so on. This search reported 26 trials after the duplicate removal and the selection reported in the materials and methods section. In each study, a very large number of potential endpoints were available. In order to focus the analysis on those endpoints reported in the vast majority of studies included, we performed a first analysis to identify the most significant (in terms of number of availability) outcomes. This result was graphed into Figure 2, now supplementary figure 1. We highlighted this decision process within the text as follows: "The analysis was limited to those parameters entering in the cardiovascular risk charts and those related to endothelial dysfunction. In general, the most reported parameters were: cholesterol, blood pressure, tumor necrosis factor (TNF), IL-6, flow mediated dilation (FMD), fibrinogen, body mass index (BMI), glucose, insulin, adiponectin and high sensitivity C-reactive protein (hs-CRP). However, not all parameters were available in all studies. Thus, we performed a work diagram (Supplementary figure 1) in which the font dimension is directly related to the number of studies reporting each parameter. Considering those parameters reported in the vast majority of studies (Supplementary figure 1), the analysis was limited to lipid profile, blood pressure, FMD, fibrinogen, adiponectin, hs-CRP, TNF and IL-6".

Comment 4

In line 135-137, how to define acute beer administration or chronic administration by the duration of beer administration in each study enrolled? And the results of sensitivity analyses should be presented in the main test or supplemental material. As the heterogeneity in your results is pretty high, more sensitivity analyses, such as stratified by age, sex, BMI and so on, should be implemented in order to explore the source of high heterogeneity.

ANSWER: Thank you for your suggestion.

The distinction between acute and chronic beer administration depends on the time of outcome measure. In particular, whether the protocol provided one beer administration, followed by outcomes measurement, it was defined as acute. On the contrary, if the outcome measure occurred after many beer administrations, it defined a chronic assumption. We better specified this point within the materials and methods section as follows: "The acute or chronic administration was defined according to the amount of beer administered. In particular, the acute protocol provided a single beer assumption, followed by outcomes measurement. On the contrary, the chronic protocol consisted of many beer administrations in a prolonged time-frame interval and followed by the outcome detection".

Moreover, we included new sensitivity analyses considering the gender and the health status of the subjects. We included these new analyses in both the materials and methods and in the results sections.

Comment 5、

In line 148-152, you mentioned "The most reported parameters were: cholesterol, blood pressure, tumor necrosis factor (TNF), IL-6, flow mediated dilation (FMD), fibrinogen, body mass index (BMI), glucose, insulin, adiponectin and high sensitivity C-reactive protein (hs-CRP). Thus, the analysis was limited to those parameters entering in the cardiovascular risk charts (lipid profile and blood pressure) and those related to endothelial dysfunction (i.e. FMD, fibrinogen, adiponectin, hs-CRP, TNF and IL-6)". Since BMI, glucose and insulin were also the most reported parameters and were included in the cardiovascular risk charts, why your results did not include these results?

ANSWER: We agree with your suggestion. However, we did not consider BMI, glucose and insulin in the analysis, since they were reported in a limited number of studies included. This is reported in the actual supplementary figure 1. We specified this point in the main text as follows: "The analysis was limited to those parameters entering in the cardiovascular risk charts and those related to endothelial dysfunction. In general, the most reported parameters were: cholesterol, blood pressure, tumor necrosis factor (TNF), IL-6, flow mediated dilation (FMD), fibrinogen, body mass index (BMI), glucose, insulin, adiponectin and high sensitivity C-reactive protein (hs-CRP). However, not all parameters were available in all studies. Thus, we performed a work diagram (Supplementary figure 1) in which the font dimension is directly related to the number of studies reporting each parameter. Considering those parameters reported in the vast majority of studies (Supplementary figure 1), the analysis was limited to lipid profile, blood pressure, FMD, fibrinogen, adiponectin, hs-CRP, TNF and IL-6."

Comment 6

In line 150-152, you said "the analysis was limited to...those related to endothelial dysfunction (i.e. FMD, fibrinogen, adiponectin, hs-CRP, TNF and IL-6)..". According to previous studies, adiponectin, hs-CRP, TNF and IL-6 should be categoried as inflammation, not as endothelial dysfunction. Fibrinogen should be categoried as coagulation, not as endothelial dysfunction. Please refer to "Haseeb S, Alexander B, Baranchuk A. Wine and Cardiovascular Health: A Comprehensive Review. Circulation. 2017;136(15):1434--1448."

ANSWER: We changed this sentence, according to your previous comment and in order to avoid confusion and to be more polite. Now, this paragraph is as follows: "The analysis was limited to those parameters entering in the cardiovascular risk charts and those related to endothelial dysfunction. In general, the most reported parameters were: cholesterol, blood pressure, tumor necrosis factor (TNF), IL-6, flow mediated dilation (FMD), fibrinogen, body mass index (BMI), glucose, insulin, adiponectin and high sensitivity C-reactive protein (hs-CRP). However, not all parameters were available in all studies. Thus, we performed a work diagram (Supplementary figure 1) in which the font dimension is directly related to the number of studies reporting each parameter. Considering those parameters reported in the vast majority of studies (Supplementary figure 1), the analysis was limited to lipid profile, blood pressure, FMD, fibrinogen, adiponectin, hs-CRP, TNF and IL-6."

Comment 7

The retrieval strategies should be more standard and accurate, and should be better list in a table. Please refer to：Lin X, Zhang X, Guo J, et al. Effects of Exercise Training on Cardiorespiratory Fitness and Biomarkers of Cardiometabolic Health: A Systematic Review and Meta-Analysis of Randomized Controlled Trials. J Am Heart Assoc. 2015;4(7):e002014.

ANSWER: Dear reviewer, the description of the literature search could be useful but, at the same time, confusing. We followed the indication proposed by the Cochrane collaboration and we decided to keep the literature search description as suggested by their statement. We included, in the materials and methods section, the reference of Cochrane collaboration handbook (Higgins JPT, Thomas J, Chandler J, Cumpston M, Page MJ, Welch VA. Cochrane Handbook for Systematic Reviews of Interventions 2nd Edition. Higgins JPT, Thomas J, Chandler J, Cumpston M, Page MJ, Welch VA, editors. Chichester (UK): John Wiley & Sons; 2019).

Comment 8

Publication bias should be evaluated not only inspecting the Funnel plot, but also implementing the Begg's adjusted rank correlation test and the Egger's regression test.

ANSWER: Thank you for your suggestion. We included the Eggert's analysis to evaluate the possible presence of publication biases.

Comment 9

Mean difference in results and figures should be described as "Weighted mean difference (WMD)"

ANSWER: The outcome measurement is quite standard for those endpoints reported. Thus, as suggested by the Cochrane Collaboration, it is no mandatory to report differences as standardized mean difference, but it should be reported as mean differences.

Comment 10

In Figure 1, the reason for excluded records should be specified. And the "Study included in qualitative synthesis" box is redundant.

ANSWER: Thank you. We updated the figure 1 as you suggested.

Reviewer \#2:

The paper by Spaggiari et al. evaluated the potential effect of beer consumption on cardiovascular health, exemplified as lipid metabolism, endothelial function and blood pressure, using a meta-analytic approach. Totally twenty-six randomized controlled trials were included in the current analyses, beer consumption was associated with higher HDL cholesterol, apoA1 and FMD, whereas not related to blood pressure.

Brief review of the paper:

Comment 1

In Abstract, lines 27-28, "...The literature search, comprising all English articles published until November, 30th 2018 in EMBASE..." was inconsistent with the time mentioned in methods (page 5, line 101). Please check.

ANSWER: Thank you, we aligned the two parts

Comment 2

In the last sentence of Abstract, the authors conclude "moderate beer drinkers seem not to be discouraged". However, Table 1 reporting characteristic of included trials did not include the level of beer consumption. It was hard to conclude whether moderate or high beer drinkers was beneficial from the current analyses. Estimate of the regression coefficient could be used to illustrate the dose-dependent association between beer consumption and cardiovascular markers.

ANSWER: Thank you for this observation. According to your suggestion and to previous comments, we updated the Table 1, reporting all data available and useful to understand the alcohol intake during the study protocol.

Comment 3

Following Question 2, according to eligibility criteria mentioned in Methods (page 5, lines 105-109), only randomized studies were included, but Table 1 emphasized the "randomized trials" in study design which may cause confusion.

ANSWER: Thank you. We deleted the "randomized trials" in the table 1

Comment 4

Of note, wine and spirit-controlled studies were also included, were these active controlled regarded as water? (Figure 4)

ANSWER: In studies in which other alcohol beverages were used, only the group in which beer was administered were considered and compared to water or alcohol-free beer.

Comment 5

Please check the data collected in the current analyses carefully. For example, Table 1, the study by Puddey IB (Hypertension 1992) was done in 86 overweight men (not healthy men) for an 18-week intervention of low or normal alcohol intake (not beer, alcoholic and not-alcoholic).\[1\]

ANSWER: We corrected the definition of included patients in the work by Puddey et al. 1992. However, in this trial it is possible to obtain those patients in which only beer was administered.

Comment 6

The acute effect of beer should be separated from the long-term effect, especially on blood pressure and FMD. Acute beer consumption would increase heart rate, dilate peripheral arteries and therefore reduce blood pressure, whether the continuing decline after long-term of alcohol consumption was of interest.

ANSWER: Thank you for your suggestion. We included this idea within the discussion section as follows: "The beneficial effect of acute beer intake on vascular endothelial function is well described (41), leading to the heart rate increase, the peripheral arteries dilation and the blood pressure reduction. In line with this aspect, our results support that this improvement is maintained also for moderate beer intake, especially considering blood pressure and FMD."
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To beer or not to beer: a meta-analysis of beer consumption on cardiovascular health

PLOS ONE

Dear Dr. Cignarelli,

Thank you for submitting your manuscript to PLOS ONE. After careful consideration, we feel that it has merit but does not fully meet PLOS ONE's publication criteria as it currently stands. Therefore, we invite you to submit a revised version of the manuscript that addresses the points raised during the review process.

Specifically, please, do check if the included trials reached the inclusion criteria of the current investigation, and ensure data accuracy of the tables and figures. 

We would appreciate receiving your revised manuscript by Jun 13 2020 11:59PM. When you are ready to submit your revision, log on to <https://www.editorialmanager.com/pone/> and select the \'Submissions Needing Revision\' folder to locate your manuscript file.

If you would like to make changes to your financial disclosure, please include your updated statement in your cover letter.

To enhance the reproducibility of your results, we recommend that if applicable you deposit your laboratory protocols in protocols.io, where a protocol can be assigned its own identifier (DOI) such that it can be cited independently in the future. For instructions see: <http://journals.plos.org/plosone/s/submission-guidelines#loc-laboratory-protocols>

Please include the following items when submitting your revised manuscript:

A rebuttal letter that responds to each point raised by the academic editor and reviewer(s). This letter should be uploaded as separate file and labeled \'Response to Reviewers\'.A marked-up copy of your manuscript that highlights changes made to the original version. This file should be uploaded as separate file and labeled \'Revised Manuscript with Track Changes\'.An unmarked version of your revised paper without tracked changes. This file should be uploaded as separate file and labeled \'Manuscript\'.

Please note while forming your response, if your article is accepted, you may have the opportunity to make the peer review history publicly available. The record will include editor decision letters (with reviews) and your responses to reviewer comments. If eligible, we will contact you to opt in or out.

We look forward to receiving your revised manuscript.

Kind regards,

Yan Li, MD, PhD

Academic Editor

PLOS ONE

\[Note: HTML markup is below. Please do not edit.\]

Reviewers\' comments:

Reviewer\'s Responses to Questions

**Comments to the Author**

1\. If the authors have adequately addressed your comments raised in a previous round of review and you feel that this manuscript is now acceptable for publication, you may indicate that here to bypass the "Comments to the Author" section, enter your conflict of interest statement in the "Confidential to Editor" section, and submit your \"Accept\" recommendation.

Reviewer \#1: (No Response)

Reviewer \#2: (No Response)

\*\*\*\*\*\*\*\*\*\*

2\. Is the manuscript technically sound, and do the data support the conclusions?

The manuscript must describe a technically sound piece of scientific research with data that supports the conclusions. Experiments must have been conducted rigorously, with appropriate controls, replication, and sample sizes. The conclusions must be drawn appropriately based on the data presented.

Reviewer \#1: No

Reviewer \#2: Partly

\*\*\*\*\*\*\*\*\*\*

3\. Has the statistical analysis been performed appropriately and rigorously?

Reviewer \#1: Yes

Reviewer \#2: Yes

\*\*\*\*\*\*\*\*\*\*

4\. Have the authors made all data underlying the findings in their manuscript fully available?

The [PLOS Data policy](http://www.plosone.org/static/policies.action#sharing) requires authors to make all data underlying the findings described in their manuscript fully available without restriction, with rare exception (please refer to the Data Availability Statement in the manuscript PDF file). The data should be provided as part of the manuscript or its supporting information, or deposited to a public repository. For example, in addition to summary statistics, the data points behind means, medians and variance measures should be available. If there are restrictions on publicly sharing data---e.g. participant privacy or use of data from a third party---those must be specified.

Reviewer \#1: Yes

Reviewer \#2: Yes

\*\*\*\*\*\*\*\*\*\*

5\. Is the manuscript presented in an intelligible fashion and written in standard English?

PLOS ONE does not copyedit accepted manuscripts, so the language in submitted articles must be clear, correct, and unambiguous. Any typographical or grammatical errors should be corrected at revision, so please note any specific errors here.

Reviewer \#1: Yes

Reviewer \#2: Yes

\*\*\*\*\*\*\*\*\*\*

6\. Review Comments to the Author

Please use the space provided to explain your answers to the questions above. You may also include additional comments for the author, including concerns about dual publication, research ethics, or publication ethics. (Please upload your review as an attachment if it exceeds 20,000 characters)

Reviewer \#1: Thanks for your effort in modifying this manuscript, most of my questions have been solved. But I still have some questions and suggestions as follows:

1\. Please re-confirm your data in table 1 precisely!

On the one hand, in line 108 to 111, you mentioned that "The following inclusion criteria were considered: (i) double-blind, randomized, controlled study design", however, Ref "Zilkens RR, Burke V, Hodgson JM, et al. Red wine and beer elevate blood pressure in normotensive men. Hypertension. 2005;45(5):874--879"," Padro T, Muñoz-García N, Vilahur G, et al. Moderate Beer Intake and Cardiovascular Health in Overweight Individuals. Nutrients. 2018;10(9):1237", "Schrieks IC, Joosten MM, Klöpping-Ketelaars WA, Witkamp RF, Hendriks HF. Moderate alcohol consumption after a mental stressor attenuates the endocrine stress response. Alcohol. 2016;57:29--34", "Chiva-Blanch G, Magraner E, Condines X, et al. Effects of alcohol and polyphenols from beer on atherosclerotic biomarkers in high cardiovascular risk men: a randomized feeding trial. Nutr Metab Cardiovasc Dis. 2015;25:36--45", Karatzi K, Rontoyanni VG, Protogerou AD, et al. Acute effects of beer on endothelial function and hemodynamics: a single-blind, crossover study in healthy volunteers. Nutrition. 2013;29:1122-6.", "Joosten MM, Witkamp RF, Hendriks HF. Alterations in total and high-molecular-weight adiponectin after 3 weeks of moderate alcohol consumption in premenopausal women. Metabolism. 2011;60:1058--1063", "Imhof A, Plamper I, Maier S, et al. Effect of drinking on adiponectin in healthy men and women: a randomized intervention study of water, ethanol, red wine, and beer with or without alcohol. Diabetes Care. 2009;32:1101--1103" and so on are even not double-blind study.

On the other hand, in Ref "Tomita J, Mochizuki S, Fujimoto S, et al. Acute improvement of endothelial functions after oral ingestion of isohumulones, bitter components of beer. Biochem Biophys Res Commun. 2017;484(4):740--745", the total number is 23, not 31.

In conclusion, the accuracy of the data in this article is questionable.

2\. In line 39-40, you mentioned "In conclusion, the specific beer effect on human cardiovascular health was evaluated for the first time", in line 329-331, you also mentioned "In conclusion, this is the first comprehensive evaluation of beer properties in the cardiovascular setting...", however, as far as I know, there exists some researches have already evaluated the beer effect on human cardiovascular health, do you mean this paper is "the first comprehensive meta-analysis specific beer effect on human cardiovascular health"? Please clarify.

3\. In table 1 and each forest plots, please add the corresponding reference number so as to assist the reader to find the reference.

Reviewer \#2: 1) As is clarified in the revised manuscript (page 4 lines 4-6), a moderate beer consumption was defined by the World Health Organization (WHO) as up to a can of 330 mL of beer containing about 5% w/v alcohol daily for women and up to 2 for men, which was equivalent to 16.5g/d for women and 33g/d for men. However, the levels of alcohol content were beyond this range in several studies listed in Table 1. Could they be regarded as moderate beer consumption?

2\) When it comes to the beneficial effect of beer on endothelial function raised by authors (page 2, lines 42-44, page 14, lines 286-295), the conclusion was based on the results of 4 trials, of which 2 were acute effect whereas others were chronic effect. The improvement of FMD was predominantly derived from the significant acute effect of two trials (Figure 5), which should be emphasized in conclusion. Following Reviewer 2 Comment 6, the beneficial effect of beer on endothelial function remained to be illustrated.

3\) On page 12, lines 246-247, the authors discussed "The effect on total cholesterol seems to be mainly related to the acute effect rather than the chronic one", which was inconsistent with the results of sensitivity analyses, the difference between beer group and alcohol-free beer group was statistically significant (page 8, lines 172-175).

\*\*\*\*\*\*\*\*\*\*

7\. PLOS authors have the option to publish the peer review history of their article ([what does this mean?](https://journals.plos.org/plosone/s/editorial-and-peer-review-process#loc-peer-review-history)). If published, this will include your full peer review and any attached files.

If you choose "no", your identity will remain anonymous but your review may still be made public.

**Do you want your identity to be public for this peer review?** For information about this choice, including consent withdrawal, please see our [Privacy Policy](https://www.plos.org/privacy-policy).

Reviewer \#1: No

Reviewer \#2: No

\[NOTE: If reviewer comments were submitted as an attachment file, they will be attached to this email and accessible via the submission site. Please log into your account, locate the manuscript record, and check for the action link \"View Attachments\". If this link does not appear, there are no attachment files to be viewed.\]

While revising your submission, please upload your figure files to the Preflight Analysis and Conversion Engine (PACE) digital diagnostic tool, <https://pacev2.apexcovantage.com/>. PACE helps ensure that figures meet PLOS requirements. To use PACE, you must first register as a user. Registration is free. Then, login and navigate to the UPLOAD tab, where you will find detailed instructions on how to use the tool. If you encounter any issues or have any questions when using PACE, please email us at <figures@plos.org>. Please note that Supporting Information files do not need this step.
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Author response to Decision Letter 1

2 May 2020

Comments to the Author

Reviewer \#1

Thanks for your effort in modifying this manuscript, most of my questions have been solved. But I still have some questions and suggestions as follows:

Comment 1

1\. Please re-confirm your data in table 1 precisely!

ANSWER: We revised the table 1.

Comment 2

On the one hand, in line 108 to 111, you mentioned that "The following inclusion criteria were considered: (i) double-blind, randomized, controlled study design", however, Ref "Zilkens RR, Burke V, Hodgson JM, et al. Red wine and beer elevate blood pressure in normotensive men. Hypertension. 2005;45(5):874--879"," Padro T, Muñoz-García N, Vilahur G, et al. Moderate Beer Intake and Cardiovascular Health in Overweight Individuals. Nutrients. 2018;10(9):1237", "Schrieks IC, Joosten MM, Klöpping-Ketelaars WA, Witkamp RF, Hendriks HF. Moderate alcohol consumption after a mental stressor attenuates the endocrine stress response. Alcohol. 2016;57:29--34", "Chiva-Blanch G, Magraner E, Condines X, et al. Effects of alcohol and polyphenols from beer on atherosclerotic biomarkers in high cardiovascular risk men: a randomized feeding trial. Nutr Metab Cardiovasc Dis. 2015;25:36--45", Karatzi K, Rontoyanni VG, Protogerou AD, et al. Acute effects of beer on endothelial function and hemodynamics: a single-blind, crossover study in healthy volunteers. Nutrition. 2013;29:1122-6.", "Joosten MM, Witkamp RF, Hendriks HF. Alterations in total and high-molecular-weight adiponectin after 3 weeks of moderate alcohol consumption in premenopausal women. Metabolism. 2011;60:1058--1063", "Imhof A, Plamper I, Maier S, et al. Effect of drinking on adiponectin in healthy men and women: a randomized intervention study of water, ethanol, red wine, and beer with or without alcohol. Diabetes Care. 2009;32:1101--1103" and so on are even not double-blind study.

ANSWER: Thank you for your observation. This is a misprint. Indeed, we included all controlled trials, not necessarily double-blinded. We corrected the inclusion criteria part accordingly.

Comment 2

On the other hand, in Ref "Tomita J, Mochizuki S, Fujimoto S, et al. Acute improvement of endothelial functions after oral ingestion of isohumulones, bitter components of beer. Biochem Biophys Res Commun. 2017;484(4):740--745", the total number is 23, not 31.

In conclusion, the accuracy of the data in this article is questionable.

ANSWER: We revised the manuscript, as reported in comment 1

Comment 3

In line 39-40, you mentioned "In conclusion, the specific beer effect on human cardiovascular health was evaluated for the first time", in line 329-331, you also mentioned "In conclusion, this is the first comprehensive evaluation of beer properties in the cardiovascular setting...", however, as far as I know, there exists some researches have already evaluated the beer effect on human cardiovascular health, do you mean this paper is "the first comprehensive meta-analysis specific beer effect on human cardiovascular health"? Please clarify.

ANSWER: Thank you. We agree and we corrected the discussion as you suggested.

Comment 4

In table 1 and each forest plots, please add the corresponding reference number so as to assist the reader to find the reference.

ANSWER: We added the references to table 1 and to forest plots.

Reviewer \#2:

Comment 1

As is clarified in the revised manuscript (page 4 lines 4-6), a moderate beer consumption was defined by the World Health Organization (WHO) as up to a can of 330 mL of beer containing about 5% w/v alcohol daily for women and up to 2 for men, which was equivalent to 16.5g/d for women and 33g/d for men. However, the levels of alcohol content were beyond this range in several studies listed in Table 1. Could they be regarded as moderate beer consumption?

ANSWER: Thank you for this clarification. We considered that an average moderate beer consumption could be considered in our work. Indeed, first only some studies the daily beer administration was higher than those defined as moderate consumption, although this was a slight increase. Second, in these works, the authors themselves defined these dosages as moderate consumption. Thus, considering together these points, we could consider that on average this is a moderate beer consumption.

Comment 2

When it comes to the beneficial effect of beer on endothelial function raised by authors (page 2, lines 42-44, page 14, lines 286-295), the conclusion was based on the results of 4 trials, of which 2 were acute effect whereas others were chronic effect. The improvement of FMD was predominantly derived from the significant acute effect of two trials (Figure 5), which should be emphasized in conclusion. Following Reviewer 2 Comment 6, the beneficial effect of beer on endothelial function remained to be illustrated.

ANSWER: It is true. Probably, the beneficial effect of beer consumption on endothelial function is mainly due to acute administration, rather than chronic. We added this speculation in the discussion section as follows:

"However, this beneficial effect on endothelial function comes mainly from studies in which an acute beer administration is provided, confirming those studies in the literature in which a vascular endothelial function improvement is described after acute beer intake (41). Indeed, the acute intake could lead to the heart rate increase, the peripheral arteries dilation and the blood pressure reduction".

Comment 3

On page 12, lines 246-247, the authors discussed "The effect on total cholesterol seems to be mainly related to the acute effect rather than the chronic one", which was inconsistent with the results of sensitivity analyses, the difference between beer group and alcohol-free beer group was statistically significant (page 8, lines 172-175).

ANSWER: thank you for this clarification, we deleted this sentence since not supported by data.
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Dear Dr. Cignarelli,

We are pleased to inform you that your manuscript has been judged scientifically suitable for publication and will be formally accepted for publication once it complies with all outstanding technical requirements.

Within one week, you will receive an e-mail containing information on the amendments required prior to publication. When all required modifications have been addressed, you will receive a formal acceptance letter and your manuscript will proceed to our production department and be scheduled for publication.

Shortly after the formal acceptance letter is sent, an invoice for payment will follow. To ensure an efficient production and billing process, please log into Editorial Manager at <https://www.editorialmanager.com/pone/>, click the \"Update My Information\" link at the top of the page, and update your user information. If you have any billing related questions, please contact our Author Billing department directly at <authorbilling@plos.org>.

If your institution or institutions have a press office, please notify them about your upcoming paper to enable them to help maximize its impact. If they will be preparing press materials for this manuscript, you must inform our press team as soon as possible and no later than 48 hours after receiving the formal acceptance. Your manuscript will remain under strict press embargo until 2 pm Eastern Time on the date of publication. For more information, please contact <onepress@plos.org>.

With kind regards,

Yan Li, MD, PhD

Academic Editor

PLOS ONE

Additional Editor Comments (optional):

Reviewers\' comments:

Reviewer\'s Responses to Questions

**Comments to the Author**

1\. If the authors have adequately addressed your comments raised in a previous round of review and you feel that this manuscript is now acceptable for publication, you may indicate that here to bypass the "Comments to the Author" section, enter your conflict of interest statement in the "Confidential to Editor" section, and submit your \"Accept\" recommendation.

Reviewer \#1: All comments have been addressed

Reviewer \#2: (No Response)

\*\*\*\*\*\*\*\*\*\*

2\. Is the manuscript technically sound, and do the data support the conclusions?

The manuscript must describe a technically sound piece of scientific research with data that supports the conclusions. Experiments must have been conducted rigorously, with appropriate controls, replication, and sample sizes. The conclusions must be drawn appropriately based on the data presented.

Reviewer \#1: Yes

Reviewer \#2: (No Response)

\*\*\*\*\*\*\*\*\*\*

3\. Has the statistical analysis been performed appropriately and rigorously?

Reviewer \#1: Yes

Reviewer \#2: (No Response)

\*\*\*\*\*\*\*\*\*\*

4\. Have the authors made all data underlying the findings in their manuscript fully available?

The [PLOS Data policy](http://www.plosone.org/static/policies.action#sharing) requires authors to make all data underlying the findings described in their manuscript fully available without restriction, with rare exception (please refer to the Data Availability Statement in the manuscript PDF file). The data should be provided as part of the manuscript or its supporting information, or deposited to a public repository. For example, in addition to summary statistics, the data points behind means, medians and variance measures should be available. If there are restrictions on publicly sharing data---e.g. participant privacy or use of data from a third party---those must be specified.

Reviewer \#1: Yes

Reviewer \#2: (No Response)

\*\*\*\*\*\*\*\*\*\*

5\. Is the manuscript presented in an intelligible fashion and written in standard English?

PLOS ONE does not copyedit accepted manuscripts, so the language in submitted articles must be clear, correct, and unambiguous. Any typographical or grammatical errors should be corrected at revision, so please note any specific errors here.

Reviewer \#1: Yes

Reviewer \#2: (No Response)

\*\*\*\*\*\*\*\*\*\*

6\. Review Comments to the Author

Please use the space provided to explain your answers to the questions above. You may also include additional comments for the author, including concerns about dual publication, research ethics, or publication ethics. (Please upload your review as an attachment if it exceeds 20,000 characters)

Reviewer \#1: (No Response)

Reviewer \#2: (No Response)

\*\*\*\*\*\*\*\*\*\*

7\. PLOS authors have the option to publish the peer review history of their article ([what does this mean?](https://journals.plos.org/plosone/s/editorial-and-peer-review-process#loc-peer-review-history)). If published, this will include your full peer review and any attached files.

If you choose "no", your identity will remain anonymous but your review may still be made public.

**Do you want your identity to be public for this peer review?** For information about this choice, including consent withdrawal, please see our [Privacy Policy](https://www.plos.org/privacy-policy).

Reviewer \#1: No

Reviewer \#2: No

10.1371/journal.pone.0233619.r006

Acceptance letter

Li

Yan

Academic Editor

© 2020 Yan Li

2020

Yan Li

This is an open access article distributed under the terms of the

Creative Commons Attribution License

, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

13 May 2020

PONE-D-20-01229R2

To beer or not to beer: a meta-analysis of the effects of beer consumption on cardiovascular health

Dear Dr. Cignarelli:

I am pleased to inform you that your manuscript has been deemed suitable for publication in PLOS ONE. Congratulations! Your manuscript is now with our production department.

If your institution or institutions have a press office, please notify them about your upcoming paper at this point, to enable them to help maximize its impact. If they will be preparing press materials for this manuscript, please inform our press team within the next 48 hours. Your manuscript will remain under strict press embargo until 2 pm Eastern Time on the date of publication. For more information please contact <onepress@plos.org>.

For any other questions or concerns, please email <plosone@plos.org>.

Thank you for submitting your work to PLOS ONE.

With kind regards,

PLOS ONE Editorial Office Staff
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Professor Yan Li

Academic Editor
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